Kinetics of B Cell Response in Infants Menjugate Vaccination

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00310700
Recruitment Status : Completed
First Posted : April 4, 2006
Last Update Posted : September 19, 2014
Novartis Vaccines
Information provided by:

Brief Summary:
Kinetics of B cell response in infants Menjugate vaccination

Condition or disease Intervention/treatment Phase
Prevention of Meningococcal Infection Biological: Meningococcal C conjugate vaccine Phase 4

Study Type : Interventional  (Clinical Trial)
Enrollment : 75 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: A Phase IV, Single Centre, Open-label Study to Investigate the Kinetics of the B Cell Response to the First and the Third Immunization With Chiron Meningococcal C Conjugate Vaccine Administered to Healthy Infants at 2, 3 and 4 Months of Age
Study Start Date : May 2005
Actual Primary Completion Date : November 2005
Actual Study Completion Date : November 2005

Resource links provided by the National Library of Medicine

U.S. FDA Resources

Primary Outcome Measures :
  1. To establish at which day meningococcal C specific B cells are detectable in the blood of healthy infants following first and third immunisation with MenC Conjugate Vaccine as determined by Men C specific B-cell ELISPot assay.

Secondary Outcome Measures :
  1. To establish how long the B cells persist in the blood
  2. To note the difference between plasma cell response following the first and third MenC vaccination.
  3. To determine the immune response to Neisseria meningitidis serogroup C 26-34 days after the third immunisation

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   8 Weeks to 11 Weeks   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • healthy infants

Exclusion Criteria:

  • previously ascertained or suspected disease caused by N. meningitidis
  • previous household contact with an individual with a positive culture of N. meningitidis serogroup C

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00310700

United Kingdom
Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital
Oxford, Oxon, United Kingdom, OX3 7LJ
Sponsors and Collaborators
Novartis Vaccines
Principal Investigator: Novartis Vaccines - Information Services Novartis Vaccines & Diagnostics

Publications: Identifier: NCT00310700     History of Changes
Other Study ID Numbers: M14P5
Impact N° 1457
2004-004962-33 ( EudraCT Number )
First Posted: April 4, 2006    Key Record Dates
Last Update Posted: September 19, 2014
Last Verified: September 2014

Keywords provided by Novartis:
Prevention of Meningococcal Meningitis
vaccines, conjugate
antibody persistence

Additional relevant MeSH terms:
Meningococcal Infections
Neisseriaceae Infections
Gram-Negative Bacterial Infections
Bacterial Infections
Immunologic Factors
Physiological Effects of Drugs